| Bioactivity | [Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (Kd=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy[1]. |
| CAS | 2042178-19-6 |
| Sequence | Lys-Arg-His-Arg-{Nle}-Val-Leu-Arg |
| Shortening | KRHR-{Nle}-VLR |
| Formula | C47H88N20O9 |
| Molar Mass | 1077.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Judge R A, et al. Turning a substrate peptide into a potent inhibitor for the histone methyltransferase SETD8[J]. ACS Medicinal Chemistry Letters, 2016, 7(12): 1102-1106. |
[Nle20] H4 peptide (16−23)
CAS: 2042178-19-6 F: C47H88N20O9 W: 1077.33
H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (Kd=0.14 μM),
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.